Human TNFRSF11B Protein 2975

$300.00 – $1,000.00

Summary

Expression: HEK293
Functional: Yes (ELISA)
Amino Acid Range: Glu22-Leu401

SKU: 2975parent Categories: proteins, Recombinant proteins Tag: active proteins

Weight	1 lbs
Dimensions	9 × 5 × 2 in
accession	O00300
express system	HEK293
product tag	C-His
purity	> 95% as determined by Tris-Bis PAGE
background	Osteoprotegerin (OPG) is a key regulator in bone metabolism, that also has effect in vascular system. Studies suggest that osteoprotegerin is a critical arterial calcification inhibitor, and is released by endothelial cells as a protective mechanism for their survival in certain pathological conditions, such as diabetes mellitus, chronic kidney disease, and other metabolic disorders.
molecular weight	The protein has a predicted MW of 44.71 kDa. Due to glycosylation, the protein migrates to 55-65 kDa based on Tris-Bis PAGE result.
available size	100 µg, 500 µg
endotoxin	Less than 1EU per μg by the LAL method.

Human TNFRSF11B Protein 2975

protein
Size and concentration
100, 500µg and lyophilized
Form
Lyophilized
Storage Instructions
Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Storage buffer
Shipped at ambient temperature.
Purity
> 95% as determined by Tris-Bis PAGE
target relevance
Osteoprotegerin (OPG) is a key regulator in bone metabolism, that also has effect in vascular system. Studies suggest that osteoprotegerin is a critical arterial calcification inhibitor, and is released by endothelial cells as a protective mechanism for their survival in certain pathological conditions, such as diabetes mellitus, chronic kidney disease, and other metabolic disorders.
Protein names
Tumor necrosis factor receptor superfamily member 11B (Osteoclastogenesis inhibitory factor) (Osteoprotegerin)
Gene names
TNFRSF11B,TNFRSF11B OCIF OPG
Mass
9606Da
Function
Acts as a decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis.
Subellular location
Secreted.
Tissues
Highly expressed in adult lung, heart, kidney, liver, spleen, thymus, prostate, ovary, small intestine, thyroid, lymph node, trachea, adrenal gland, testis, and bone marrow. Detected at very low levels in brain, placenta and skeletal muscle. Highly expressed in fetal kidney, liver and lung.
Structure
Homodimer. Interacts with TNFSF10 and TNFSF11.
Post-translational modification
N-glycosylated. Contains sialic acid residues.; The N-terminus is blocked.
Target Relevance information above includes information from UniProt accession: O00300
The UniProt Consortium

Data

Human TNFRSF11B, His Tag captured on CM5 Chip via Anti-His Antibody can bind Human RANKL, No Tag with an affinity constant of 0.030 nM as determined in SPR assay (Biacore T200).

Immobilized Human RANKL, No Tag at 2µg/ml (100µl/Well) on the plate. Dose response curve for Human TNFRSF11B, His Tag with the EC50 of 16.8ng/ml determined by ELISA (QC Test).

Human TNFRSF11B on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

Publications

pmid	title	authors	citation
We haven't added any publications to our database yet.

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.